Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 19 May 2017 Planned End Date changed from 1 Jun 2021 to 1 May 2021.
- 19 May 2017 Planned primary completion date changed from 1 Jun 2021 to 1 May 2021.
- 19 May 2017 Status changed from not yet recruiting to recruiting.